Targeting: The ADEPT Story So Far
Antibody-directed enzyme prodrug therapy aims to restrict the action of a cytotoxic drug to cancer sites. An enzyme that has no human analogue is delivered to cancer sites by attachment to an antibody directed at a tumour associated antigen. In a second step an antibody or other agent inactivates and clears enzyme from blood. The third step is administration of a low toxicity prodrug that is a substrate for the enzyme thus generating a potent cytotoxic agent at cancer sites. Encouraging results were obtained with this system in small scale clinical trials using unrefined agents. During the past 10 years attempts have been made to reduce the system to two components. Although these have met with some success it is now accepted that future progress requires all three components.
No Supplementary Data
Document Type: Research Article
Publication date: 2009-02-01
More about this publication?
- Current Drug Targets aims to cover the latest and most outstanding developments on the medicinal chemistry and pharmacology of molecular drug targets e.g. disease specific proteins, receptors, enzymes, genes. Each issue of the journal will be devoted to a single timely topic, with series of in-depth reviews, written by leaders in the field, covering a range of current topics on drug targets. These issues will be organized and led by a guest editor who is a recognized expert in the overall topic. As the discovery, identification, characterisation and validation of novel human drug targets for drug discovery continues to grow; this journal will be essential reading for all pharmaceutical scientists involved in drug discovery and development.